Literature DB >> 22674940

Chronic inflammatory demyelinating polyradiculoneuropathy complicating anti TNF α therapy for chronic plaque psoriasis.

Zahra Ahmed1, Robert Powell, Gareth Llewelyn, Alex Anstey.   

Abstract

A 53-year-old woman with chronic plaque psoriasis treated with adalimumab (antitumour necrosis factor (anti TNF) α therapy) for 10 months presented with an 8 week history of hyperesthesia in a 'glove and stocking' distribution and clumsiness on walking. Nerve conduction studies confirmed the clinical diagnosis of a chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). She was admitted and treated with intravenous immunoglobulin and oral steroids and made an excellent recovery. To our knowledge, this is the first published report of CIDP associated with anti TNF α therapy given to treat psoriasis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22674940      PMCID: PMC3229329          DOI: 10.1136/bcr.08.2011.4674

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  5 in total

Review 1.  Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?

Authors:  W H Robinson; M C Genovese; L W Moreland
Journal:  Arthritis Rheum       Date:  2001-09

2.  Chronic inflammatory demyelinating polyneuropathy associated with tumor necrosis factor-alpha antagonists.

Authors:  Amer Alshekhlee; Kevian Basiri; J Douglas Miles; Saef A Ahmad; Bashar Katirji
Journal:  Muscle Nerve       Date:  2010-05       Impact factor: 3.217

Review 3.  Demyelination and inhibition of tumor necrosis factor (TNF).

Authors:  M D Magnano; W H Robinson; M C Genovese
Journal:  Clin Exp Rheumatol       Date:  2004 Sep-Oct       Impact factor: 4.473

4.  Recurrent Guillain Barre' syndrome.

Authors:  A Das; J Kalita; U K Misra
Journal:  Electromyogr Clin Neurophysiol       Date:  2004-03

5.  Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy.

Authors:  Pierre Lozeron; Christian Denier; Catherine Lacroix; David Adams
Journal:  Arch Neurol       Date:  2009-04
  5 in total
  4 in total

Review 1.  Neurological Complications of Therapeutic Monoclonal Antibodies: Trends from Oncology to Rheumatology.

Authors:  Chandler Gill; Stasia Rouse; Ryan D Jacobson
Journal:  Curr Neurol Neurosci Rep       Date:  2017-08-17       Impact factor: 5.081

Review 2.  Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Mohamed Mahdi-Rogers; Ruth Brassington; Angela A Gunn; Pieter A van Doorn; Richard Ac Hughes
Journal:  Cochrane Database Syst Rev       Date:  2017-05-08

3.  Non-length-dependent and length-dependent small-fiber neuropathies associated with tumor necrosis factor (TNF)-inhibitor therapy in patients with rheumatoid arthritis: expanding the spectrum of neurological disease associated with TNF-inhibitors.

Authors:  Julius Birnbaum; Clifton O Bingham
Journal:  Semin Arthritis Rheum       Date:  2013-10-30       Impact factor: 5.532

4.  Transcriptome Analysis of Peripheral Blood in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients Identifies TNFR1 and TLR Pathways in the IVIg Response.

Authors:  Alexandra Richard; Jean-Christophe Corvol; Rabab Debs; Pauline Reach; Khadija Tahiri; Wassila Carpentier; Justine Gueguen; Vincent Guillemot; Céline Labeyrie; David Adams; Karine Viala; Fleur Cohen Aubart
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.